The compound you described, **2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide**, is a synthetic chemical. It's likely a **potential drug candidate** due to its structure, which incorporates various features that could be pharmacologically relevant:
* **Benzamide core:** This structure is common in pharmaceuticals, often found in antipsychotics, anticonvulsants, and analgesics.
* **4-Pyridylmethyl substituent:** The pyridine ring is found in many drugs, and the methyl group attached to it might influence how the molecule interacts with biological targets.
* **Trifluoromethyl substituent:** This group often increases the metabolic stability and lipid solubility of a drug, making it more effective in the body.
**The Importance for Research:**
This compound likely exists as part of a **research program focused on developing novel therapeutic agents**. Researchers might be investigating its potential:
* **Target activity:** They might be exploring what biological targets (e.g., receptors, enzymes) the molecule binds to and how effectively.
* **Therapeutic potential:** Researchers are likely studying the compound's potential to treat a specific disease. This might involve testing its effectiveness in preclinical models or cell cultures.
* **Pharmacokinetic properties:** They might be assessing how the compound is absorbed, distributed, metabolized, and excreted in the body (ADME).
* **Safety profile:** Extensive safety testing is necessary before any potential drug can be considered for clinical trials.
**Important Considerations:**
* **No publicly available information:** The compound you mentioned is not widely known or researched, so it's difficult to find detailed information about its specific properties and potential therapeutic use.
* **Research confidentiality:** Research projects involving new drug candidates are often kept confidential until patents are filed or publications are released.
**In summary:** 2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide is likely a research compound being investigated for its potential therapeutic activity. Its exact properties and research importance are not readily available without access to specific research programs.
2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide: an antiangiogenic VEGF receptor kinase inhibitor with antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6398883 |
| CHEMBL ID | 153843 |
| SCHEMBL ID | 4976103 |
| MeSH ID | M0444594 |
| Synonym |
|---|
| 2-[(4-pyridyl)methyl]amino-n-[3-(trifluoromethyl)phenyl] benzamide |
| 2-[(pyridin-4-ylmethyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide |
| anthranyl amide derivative c |
| chembl153843 , |
| bdbm9503 |
| aal-993 |
| 2-(pyridin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]benzamide |
| 269390-77-4 |
| 2-[(4-pyridyl)methyl]amino-n-[3-(trifluoromethyl)phenyl]benzamide |
| SCHEMBL4976103 |
| 5t2 , |
| 2-(pyridin-4-ylmethylamino)-~{n}-[3-(trifluoromethyl)phenyl]benzamide |
| EX-A1007 |
| AKOS030525999 |
| 2-((pyridin-4-ylmethyl)amino)-n-(3-(trifluoromethyl)phenyl)benzamide |
| J-016614 |
| 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide |
| mfcd18251410 |
| NCGC00390423-01 |
| aal993;aal 993 |
| BCP18097 |
| AC-36036 |
| aal993 |
| aal 993 |
| aal 993;aal 993 |
| EC-000.2527 |
| Q27456006 |
| MS-25977 |
| vegfr tyrosine kinase inhibitor vi |
| HY-19986 |
| CS-0017710 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.3450 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 0.0674 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 (µMol) | 2.8200 | 0.0001 | 0.7128 | 10.0000 | AID219188 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 10.4000 | 0.0000 | 0.5369 | 10.0000 | AID69880 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0004 | 1.3452 | 10.0000 | AID53175 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | IC50 (µMol) | 0.3800 | 0.0006 | 0.5676 | 5.5450 | AID50766 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0003 | 0.4308 | 8.0000 | AID93094 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 0.6400 | 0.0006 | 0.8007 | 8.5000 | AID161407 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | IC50 (µMol) | 0.2360 | 0.0007 | 0.4708 | 10.0000 | AID108256 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0002 | 0.9420 | 10.0000 | AID73451 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0002 | 0.5335 | 10.0000 | AID219509 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 0.1365 | 0.0001 | 0.2914 | 7.0000 | AID1796330; AID216631; AID259703; AID261931; AID262071; AID263456; AID305869; AID392542; AID392544; AID417887; AID417888; AID513142 |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | IC50 (µMol) | 0.0180 | 0.0001 | 0.2264 | 4.9000 | AID216922; AID513144 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.0506 | 0.0000 | 0.4830 | 8.8000 | AID1796330; AID216649; AID216652; AID259702; AID259704; AID261930; AID262070; AID262072; AID263455; AID263457; AID271201; AID305870; AID305871; AID313406; AID331717; AID392541; AID392543; AID392545; AID392546; AID417884; AID417885; AID417886; AID417889; AID513143; AID538338 |
| Angiopoietin-1 receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0004 | 0.5553 | 9.0700 | AID213567 |
| Macrophage-stimulating protein receptor | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0012 | 0.2698 | 3.3700 | AID108335 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID392543 | Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 8 uM ATP by HTRF assay | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. |
| AID261930 | Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6 | 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases. |
| AID219188 | In vitro inhibition of c-Abl tyrosine kinase expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID417889 | Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2. |
| AID305869 | Inhibition of VEGFR1 by HTRF assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5 | ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. |
| AID392541 | Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. |
| AID259703 | Inhibitory activity against VEGFR1 by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. |
| AID108335 | In vitro inhibition of Met proto-oncogene tyrosine kinase (c-Met) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID213567 | In vitro inhibition of Tyrosine protein kinase receptor TIE-2 (Tek) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID417888 | Inhibition of VEGFR1 by HTRF assay in presence of 8 uM ATP | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2. |
| AID392546 | Inhibition of VEGF-induced VEGFR2 phosphorylation expressed in CHO cells in presence of 8 uM ATP by ELISA | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. |
| AID417886 | Inhibition of VEGFR2 by HTRF assay in presence of 8 uM ATP | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2. |
| AID50766 | In vitro inhibition of Colony stimulating factor 1 receptor (CSF-1R) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID313405 | Inhibition of KDR at 1 uM | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. |
| AID305871 | Inhibition of VEGFR2 by cell-based assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5 | ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. |
| AID216649 | In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID263455 | Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7 | Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. |
| AID331717 | Inhibition of KDR by ELISA | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9 | Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity. |
| AID222708 | Plasma clearance in female MAG mice at peroral dose of 50 (mg/Kg) after 1.0 hr | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID513144 | Inhibition of VEGFR-3 kinase | 2006 | Nature chemical biology, Jul, Volume: 2, Issue:7 | Rational design of inhibitors that bind to inactive kinase conformations. |
| AID108256 | In vitro inhibition of Mast/stem cell growth factor receptor (c-Kit kinase) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID216922 | In vitro inhibition of Vascular endothelial growth factor receptor 3 [VEGFR-3(Flt-4)] expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID262070 | Inhibition of VEGFR2 by enzymatic assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. |
| AID538338 | Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. |
| AID259702 | Inhibitory activity against VEGFR2 by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. |
| AID305872 | Intrinsic permeability across Caco-2 cell monolayers | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5 | ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. |
| AID271199 | Inhibition of recombinant FLT1 at 10 uM by ELISA | 2006 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19 | Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases. |
| AID331719 | Antiproliferative activity against VEGF-induced HUVEC cells | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9 | Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity. |
| AID313402 | Inhibition of EGFR at 1 uM | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. |
| AID216631 | In vitro inhibition of Vascular endothelial growth factor receptor 1 (VEGFR-1) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID219509 | In vitro inhibition of c-SRC kinase expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID86730 | Mean % inhibition of induced angiogenesis by Heparin-binding growth factor 2 at a peroral dose of 50 mg/kg in mice | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID261931 | Inhibitory activity against VEGFR-1 using 2 uM ATP by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6 | 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases. |
| AID222710 | Plasma clearance in female MAG mice at peroral dose of 50 (mg/Kg) after 2.0 hr | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID262072 | Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. |
| AID216652 | Inhibition of VEGFR induced autophosphorylation of human Vascular endothelial growth factor receptor 2 (VEGFR2) transfected in CHO cells | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID417885 | Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2. |
| AID40734 | Mean % inhibition of primary tumor growth in B16 mouse administration | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID262071 | Inhibition of VEGFR1 by enzymatic assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. |
| AID392544 | Inhibition of VEGFR1 assessed as blockade of pGAT-biotin phosphorylation in presence of 8 uM ATP by HTRF assay | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. |
| AID305870 | Inhibition of VEGFR2 by HTRF assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5 | ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. |
| AID40733 | Mean % inhibition of lymph node metastasis in B16 mouse administration | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID513143 | Inhibition of VEGFR-2 kinase | 2006 | Nature chemical biology, Jul, Volume: 2, Issue:7 | Rational design of inhibitors that bind to inactive kinase conformations. |
| AID222707 | Plasma clearance in female MAG mice at peroral dose of 50 (mg/Kg) after 0.5 hr | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID313406 | Inhibition of KDR | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. |
| AID161407 | In vitro inhibition of Platelet-derived growth factor receptor beta expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID73451 | In vitro inhibition of Fibroblast growth factor receptor expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID271200 | Inhibition of recombinant KDR at 10 uM by ELISA | 2006 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19 | Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases. |
| AID222709 | Plasma clearance in female MAG mice at peroral dose of 50 (mg/Kg) after 1.5h | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID263457 | Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7 | Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. |
| AID271201 | Inhibition of recombinant KDR at 1 uM by ELISA | 2006 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19 | Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases. |
| AID216620 | Mean % inhibition of induced angiogenesis by Vascular endothelial growth factor (VEGF) at a peroral dose of 50 mg/kg in mice | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID392565 | Intrinsic permeability across human Caco-2 cells | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. |
| AID503287 | Inhibition of VEGFR2-mediated regenerative angiogenesis in adult zebrafish tail fin vessel at 100 to 500 nM after 3 days by microscopy | 2006 | Nature chemical biology, May, Volume: 2, Issue:5 | Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. |
| AID513142 | Inhibition of VEGFR-1 kinase | 2006 | Nature chemical biology, Jul, Volume: 2, Issue:7 | Rational design of inhibitors that bind to inactive kinase conformations. |
| AID69880 | In vitro inhibition of Epidermal growth factor receptor (HER-1,ErbB) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID313404 | Inhibition of Flt1 at 1 uM | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. |
| AID53175 | In vitro inhibition of Cyclin-dependent kinase 1 (CDK-1) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID392542 | Inhibition of VEGFR1 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. |
| AID93094 | In vitro inhibition of Insulin-like growth factor I receptor expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID263461 | Intrinsic permeability in Caco-2 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7 | Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. |
| AID417884 | Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA in presence of 8 uM ATP | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2. |
| AID392545 | Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA | 2009 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4 | 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. |
| AID263456 | Inhibition of VEGFR1 phosphorylation in presence of 2 uM ATP by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7 | Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. |
| AID313401 | Growth inhibition of human A431 cells overexpressing EGFR after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1 | Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. |
| AID259704 | Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. |
| AID417887 | Inhibition of VEGFR1 by HTRF assay | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5 | (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2. |
| AID1796330 | Homogeneous Time-resolved Fluorescence (HTRF) Assay from Article 10.1016/j.bmcl.2005.10.058: \\N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.\\ | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (76.47) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.39) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||